Improved additional efficacy outcomes in patients with 1L GC/GEJC and PD-L1 scores ≥1% vs placebo + chemotherapy1,2
Additional Efficacy Outcomes: PFS, ORR, and DCR with PD-L1 ≥1%
6.9 months mPFS with TEVIMBRA + chemotherapy vs 5.9 months with placebo + chemotherapy; HR: 0.78 (95% CI: 0.67-0.91)
Improved response rates
- Nearly half of patients responded to TEVIMBRA + chemotherapy: 48% ORR (95% CI: 43%-53%) vs 41% ORR with placebo + chemotherapy (95% CI: 37%-46%)
- mDoR of 8.6 months with TEVIMBRA + chemotherapy vs 7.2 months with placebo + chemotherapy
- Nearly 90% DCR with TEVIMBRA + chemotherapy at 89.6% (95% CI: 86.3%-92.3%) vs 82.3% DCR with placebo + chemotherapy (95% CI: 78.5%-85.7%)
Limitation: Secondary endpoints were not powered for statistical comparison and are descriptive only. No definitive conclusions can be drawn.
Frequently Asked Questions
Expand All
What is the PFS with TEVIMBRA in patients with 1L GC/GEJC?
TEVIMBRA + chemotherapy reported extended median progression-free survival of 6.9 months vs 5.9 months with placebo + chemotherapy. 15.2% of patients were still alive and progression-free at 3 years with TEVIMBRA + chemotherapy vs 7.0% with placebo + chemotherapy.1,2
What are the response rates with TEVIMBRA in patients with 1L GC/GEJC?
Nearly half of patients responded to TEVIMBRA + chemotherapy: 48% ORR (95% CI: 43%-53%) vs 41% ORR with placebo + chemotherapy (95% CI: 37%-46%).1
1L, first line; CPS, combined positive score; DCR, disease control rate; GC, gastric cancer; GEJC, gastroesophageal junction cancer; HR, hazard ratio; mDoR, median duration of response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival.
References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025.
2. Moehler M, Oh DY, Kato K, et al. Adv Ther. 2025;42(5):2248-2268. doi:10.1007/s12325-025-03133-7.